These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Species distribution and fluconazole susceptibility of Candida clinical isolates in a medical center in 2002. Wang JL, Chang SC, Hsueh PR, Chen YC. J Microbiol Immunol Infect; 2004 Aug; 37(4):236-41. PubMed ID: 15340652 [Abstract] [Full Text] [Related]
3. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, Yan JJ, Yu KW, Wu JJ, Ko WC, Yang YC, Liu YC, Teng LJ, Liu CY, Luh KT. Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726 [Abstract] [Full Text] [Related]
9. In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with a broad antifungal spectrum. Tsuchimori N, Hayashi R, Kitamoto N, Asai K, Kitazaki T, Iizawa Y, Itoh K, Okonogi K. Antimicrob Agents Chemother; 2002 May; 46(5):1388-93. PubMed ID: 11959573 [Abstract] [Full Text] [Related]
19. In vitro activity of voriconazole against Candida species isolated in Taiwan. Yang YL, Cheng HH, Lo HJ. Int J Antimicrob Agents; 2004 Sep; 24(3):294-6. PubMed ID: 15325436 [Abstract] [Full Text] [Related]